Related Experiment Video
Updated: Aug 6, 2026

Model of Ischemia and Reperfusion Injury in Rabbits
Published on: November 3, 2023
The no-reflow phenomenon: A basic mechanism of myocardial ischemia and reperfusion
Thorsten Reffelmann1, Robert A Kloner
1The Heart Institute, Good Samaritan Hospital, Dept. of Cardiology, Division of Cardiovascular Medicine at Keck School of Medicine, University of Southern California, 1225 Wilshire Boulevard, Los Angeles (CA) 90017, USA.
Insights
Impaired microvascular blood flow, known as the no-reflow phenomenon, occurs after reperfusion therapy for myocardial infarction. This condition persists for weeks, impacting infarct healing and patient prognosis.
Area of Science:
- Cardiovascular Research
- Ischemia-Reperfusion Injury
- Microvascular Physiology
Background:
- Reperfusion therapy for acute myocardial infarction can lead to impaired microvascular perfusion despite restored epicardial vessel patency.
- The
Purpose of the Study:
- To characterize the no-reflow phenomenon in myocardial infarction.
- To investigate the determinants and persistence of no-reflow.
- To explore the clinical relevance of no-reflow in infarct healing and prognosis.
Main Methods:
- Utilized animal models of experimental myocardial infarction and reperfusion.
- Analyzed clinical studies on reperfusion therapy for acute myocardial infarction.
- Assessed microvascular perfusion defects, myocardial flow, and vascular alterations.
Main Results:
- Identified distinct perfusion defects and a progressive decrease in myocardial flow during reperfusion.
- Demonstrated that the no-reflow phenomenon is a fundamental mechanism in myocardial ischemia-reperfusion.
- Found that no-reflow persists for at least four weeks, correlating with infarct expansion and clinical prognosis.
Conclusions:
- The no-reflow phenomenon is a critical factor in myocardial ischemia-reperfusion injury.
- Persistent microvascular dysfunction after reperfusion significantly impacts infarct healing.
- No-reflow's pathoanatomic correlates are linked to the prognostic significance observed in clinical settings.
Abstract:
Both animal models of experimental myocardial infarction and clinical studies on reperfusion therapy for acute myocardial infarction have provided evidence of impaired tissue perfusion at the microvascular level after initiation of reperfusion despite adequate restoration of epicardial vessel patency. Characteristics of this "no-reflow" phenomenon found in basic science investigations, such as distinct perfusion defects, progressive decrease of resting myocardial flow with ongoing reperfusion and functional vascular alterations are paralleled by clinical observations demonstrating similar features during the course of reperfusion. In experimental animal investigations of coronary occlusion and reperfusion, this no-reflow phenomenon could be characterized as a fundamental mechanism of myocardial ischemia and reperfusion. Major determinants of the amount of no-reflow are the duration of occlusion, infarct size, but also the length of reperfusion, as rapid expansion of perfusion defects occurs during reperfusion. Moreover, no-reflow appears to persist over a period of at least four weeks, a period when major steps of infarct healing take place. The significant association of the degree of compromised tissue perfusion at four weeks and indices of infarct expansion, found in chronic animal models of reperfused myocardial infarction, might be the pathoanatomic correlate for the prognostic significance observed in the clinical setting.
Related Concept Videos
Myocarditis I: Introduction
Ischemic Stroke ll: Pathophysiology
